FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028138621> ?p ?o ?g. }

• W2028138621 endingPage "3058" @default.
• W2028138621 startingPage "3054" @default.
• W2028138621 abstract "Tumor-induced hypercalcemia (TIH) is essentially due to a marked stimulation of osteoclast-mediated bone resorption. An inhibition of bone formation and an enhanced tubular reabsorption of calcium play an important contributory role. These factors explain why serum calcium often rises rapidly in cancer patients and why high doses of bisphosphonates are needed to normalize bone resorption and to overcome the contributory role of the kidney.The author provides a short review of clinical trials in hypercalcemic cancer patients, with an emphasis on the most recent trials.Rehydration and bisphosphonates now constitute the standard treatment of TIH. A single-day 1500-mg infusion of clodronate achieves normocalcemia in approximately 80% of the cases. Clodronate also can be given by subcutaneous infusion that can be particularly useful in the palliative setting. A dose of 90 mg of pamidronate achieves normocalcemia in more than 90% of the patients and has a longer-lasting effect than clodronate. Newer more potent bisphosphonates, such as ibandronate and zoledronate, may improve these results, and they certainly will simplify the therapeutic schemes. Ibandronate at the dose of 6 mg normalizes serum calcium in more than 75% of the patients with moderate or severe hypercalcemia. Of note, the same doses of pamidronate and ibandronate, repeated monthly for 1-2 years, have been shown to substantially reduce the skeletal morbidity rate in normocalcemic patients with tumor bone disease. Even lower doses of zoledronate, the most potent bisphosphonate tested so far, are able to correct TIH when administered as a 30-minute infusion.Bisphosphonates have become the standard treatment for cancer hypercalcemia. Success is achieved in more than 90% of the cases. Other classes of compounds are being tested for their antiosteoclastic activity, and animal studies suggest that osteoprotegerin could be as efficient and act faster than bisphosphonates." @default.
• W2028138621 created "2016-06-24" @default.
• W2028138621 creator A5053293171 @default.
• W2028138621 date "2000-06-15" @default.
• W2028138621 modified "2023-10-17" @default.
• W2028138621 title "Current and future directions in medical therapy" @default.
• W2028138621 cites W1832685445 @default.
• W2028138621 cites W1883130365 @default.
• W2028138621 cites W1932993947 @default.
• W2028138621 cites W1937662086 @default.
• W2028138621 cites W1954585625 @default.
• W2028138621 cites W1966434911 @default.
• W2028138621 cites W1980576844 @default.
• W2028138621 cites W1993952498 @default.
• W2028138621 cites W1997364862 @default.
• W2028138621 cites W2030415413 @default.
• W2028138621 cites W2036776201 @default.
• W2028138621 cites W2052444365 @default.
• W2028138621 cites W2052544640 @default.
• W2028138621 cites W2056086968 @default.
• W2028138621 cites W2092065668 @default.
• W2028138621 cites W2094387987 @default.
• W2028138621 cites W2114487775 @default.
• W2028138621 cites W2185821257 @default.
• W2028138621 doi "https://doi.org/10.1002/1097-0142(20000615)88:12+<3054::aid-cncr23>3.0.co;2-z" @default.
• W2028138621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10898351" @default.
• W2028138621 hasPublicationYear "2000" @default.
• W2028138621 type Work @default.
• W2028138621 sameAs 2028138621 @default.
• W2028138621 citedByCount "62" @default.
• W2028138621 countsByYear W20281386212013 @default.
• W2028138621 countsByYear W20281386212014 @default.
• W2028138621 countsByYear W20281386212015 @default.
• W2028138621 countsByYear W20281386212020 @default.
• W2028138621 crossrefType "journal-article" @default.
• W2028138621 hasAuthorship W2028138621A5053293171 @default.
• W2028138621 hasConcept C121608353 @default.
• W2028138621 hasConcept C126322002 @default.
• W2028138621 hasConcept C126894567 @default.
• W2028138621 hasConcept C2776326535 @default.
• W2028138621 hasConcept C2776541429 @default.
• W2028138621 hasConcept C2777251235 @default.
• W2028138621 hasConcept C535046627 @default.
• W2028138621 hasConcept C673006 @default.
• W2028138621 hasConcept C71924100 @default.
• W2028138621 hasConceptScore W2028138621C121608353 @default.
• W2028138621 hasConceptScore W2028138621C126322002 @default.
• W2028138621 hasConceptScore W2028138621C126894567 @default.
• W2028138621 hasConceptScore W2028138621C2776326535 @default.
• W2028138621 hasConceptScore W2028138621C2776541429 @default.
• W2028138621 hasConceptScore W2028138621C2777251235 @default.
• W2028138621 hasConceptScore W2028138621C535046627 @default.
• W2028138621 hasConceptScore W2028138621C673006 @default.
• W2028138621 hasConceptScore W2028138621C71924100 @default.
• W2028138621 hasIssue "S12" @default.
• W2028138621 hasLocation W20281386211 @default.
• W2028138621 hasLocation W20281386212 @default.
• W2028138621 hasOpenAccess W2028138621 @default.
• W2028138621 hasPrimaryLocation W20281386211 @default.
• W2028138621 hasRelatedWork W1975692488 @default.
• W2028138621 hasRelatedWork W1985172769 @default.
• W2028138621 hasRelatedWork W1998201010 @default.
• W2028138621 hasRelatedWork W2070381129 @default.
• W2028138621 hasRelatedWork W2123367264 @default.
• W2028138621 hasRelatedWork W2141165895 @default.
• W2028138621 hasRelatedWork W2170205803 @default.
• W2028138621 hasRelatedWork W2405073496 @default.
• W2028138621 hasRelatedWork W2541953178 @default.
• W2028138621 hasRelatedWork W2802643624 @default.
• W2028138621 hasVolume "88" @default.
• W2028138621 isParatext "false" @default.
• W2028138621 isRetracted "false" @default.
• W2028138621 magId "2028138621" @default.
• W2028138621 workType "article" @default.